Table 3

Lung nodule malignancy prediction diagnostic test performance

DescriptionNo. of patientsSensitivity (%)Specificity (%)
Plasma ctDNA and FFPE1929188
ctDNA mutation (average of all stages)1926896
Stage I lung cancer876396
Stage II lung cancer298396
Stage III lung cancer179496
Panel of six serum biomarkers (BMs)1755183
LDA model of ctDNA and BMs (all stages)1748099
  • ctDNA.¬†circulating tumour DNA; FFPE, formalin fixed paraffin embedded; LDA, linear discriminant analysis.